Literature DB >> 19396955

Cholestasis and cholestatic syndromes.

Gideon M Hirschfield1, Elizabeth J Heathcote.   

Abstract

PURPOSE OF REVIEW: Cholestatic liver injury is encountered across a wide variety of clinical scenarios ranging from toxin-induced, genetic, to autoimmune in nature. This review summarizes recent findings from what is a burgeoning clinical field. RECENT
FINDINGS: We highlight observations from cell biology (intracellular signaling molecules), genetics (biliary transporters) and clinical studies (predictors of outcomes) that provide new directions for laboratory and clinical research.
SUMMARY: Treatments for cholestasis and cholestatic syndromes remain largely nonspecific and often ineffective. With the increased precision with which the cell biology of the cholangiocyte and the clinical description of associated diseases such as primary biliary cirrhosis and sclerosing cholangitis are understood, new approaches are likely to arise.

Entities:  

Mesh:

Year:  2009        PMID: 19396955     DOI: 10.1097/mog.0b013e32832914b4

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  11 in total

Review 1.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

Review 2.  Experimental evidence on the immunopathogenesis of primary biliary cirrhosis.

Authors:  Carlo Selmi; Francesca Meda; Anaid Kasangian; Pietro Invernizzi; Zhigang Tian; Zhexiong Lian; Mauro Podda; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2009-12-23       Impact factor: 11.530

3.  The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.

Authors:  Yongqing Wang; Hiroaki Aoki; Jing Yang; Kesong Peng; Runping Liu; Xiaojiaoyang Li; Xiaoyan Qiang; Lixin Sun; Emily C Gurley; Guanhua Lai; Luyong Zhang; Guang Liang; Masayuki Nagahashi; Kazuaki Takabe; William M Pandak; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

4.  ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.

Authors:  Dario Degiorgio; Andrea Crosignani; Carla Colombo; Domenico Bordo; Massimo Zuin; Emanuela Vassallo; Marie-Louise Syrén; Domenico A Coviello; Pier Maria Battezzati
Journal:  J Gastroenterol       Date:  2015-09-01       Impact factor: 7.527

5.  Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production.

Authors:  Connor E Bodeman; Anika L Dzierlenga; Catherine M Tally; Ryan M Mulligan; April D Lake; Nathan J Cherrington; Susan C McKarns
Journal:  J Pharmacol Exp Ther       Date:  2013-08-08       Impact factor: 4.030

Review 6.  Fibrosis in autoimmune and cholestatic liver disease.

Authors:  Melitta Penz-Österreicher; Christoph H Österreicher; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

7.  S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis.

Authors:  Lisa Reinhard; Christian Rupp; Hans-Dieter Riedel; Thomas Ruppert; Thomas Giese; Christa Flechtenmacher; Karl Heinz Weiss; Petra Kloeters-Plachky; Wolfgang Stremmel; Peter Schirmacher; Peter Sauer; Daniel Nils Gotthardt
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  Effects of hepatocyte CD14 upregulation during cholestasis on endotoxin sensitivity.

Authors:  Ming-Huei Chou; Jiin-Haur Chuang; Hock-Liew Eng; Po-Chin Tsai; Chih-Sung Hsieh; Hsiang-Chun Liu; Chiou-Huey Wang; Chih-Yun Lin; Tsun-Mei Lin
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

9.  Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis.

Authors:  Feng Jin; Du Cheng; Jun-Yan Tao; Shu-Ling Zhang; Ran Pang; Yuan-Jin Guo; Pian Ye; Ji-Hua Dong; Lei Zhao
Journal:  BMC Gastroenterol       Date:  2013-05-03       Impact factor: 3.067

10.  Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR.

Authors:  Ewa Wunsch; Marta Klak; Urszula Wasik; Malgorzata Milkiewicz; Malgorzata Blatkiewicz; Elzbieta Urasinska; Olivier Barbier; Dariusz Bielicki; Dimitrios P Bogdanos; Elwyn Elias; Piotr Milkiewicz
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.